8.87 USD
▲+0.16+7.52%
2026-08-03
市值
$710.55M
市盈率
—
EPS
-3.02
股息率
—
52 周区间
7.00 – 14.87
成交量
507.09K
Beta
0.39
目标价
25.30
52W 低 7.0052W 高 14.87
价格走势
公司简介
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical...